Yaming Hang

发表

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

K. Rhodes, S. Salloway, J. Sevigny, 2016, Nature.

Analysis of peginterferon β-1a exposure and Gd-enhanced lesion or T2 lesion response in relapsing-remitting multiple sclerosis patients

I. Nestorov, A. Deykin, Yaming Hang, 2016, Journal of Pharmacokinetics and Pharmacodynamics.

Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

K. Rhodes, S. Salloway, J. Sevigny, 2017, Nature.

Population‐Based Pharmacokinetic and Exposure‐Efficacy Analyses of Peginterferon Beta‐1a in Patients With Relapsing Multiple Sclerosis

I. Nestorov, Yue Cui, A. Deykin, 2017, Journal of clinical pharmacology.

Population PK-PD analyses of CD25 occupancy, CD56bright NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis.

I. Nestorov, A. Othman, Yaming Hang, 2016, British journal of clinical pharmacology.

Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients

J. Eron, M. Rizk, J. Zhao, 2012, Antimicrobial Agents and Chemotherapy.

Characterizing Effects of Antidiabetic Drugs on Heart Rate, Systolic and Diastolic Blood Pressure

M. Vakilynejad, Yaming Hang, M. Pfister, 2020, Clinical pharmacology and therapeutics.

Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I–III Clinical Trials

I. Nestorov, A. Othman, Yaming Hang, 2016, Clinical Pharmacokinetics.

Case Examples of Using Quantitative Pharmacology in Developing Therapeutic Proteins in Multiple Sclerosis - Peginterferon Beta-1a, Daclizumab Beta, Natalizumab

I. Nestorov, Yaming Hang, Lei Diao, 2019, Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases.

Analysis of peginterferon β-1a exposure and Gd-enhanced lesion or T2 lesion response in relapsing-remitting multiple sclerosis patients

I. Nestorov, A. Deykin, Yaming Hang, 2016, Journal of Pharmacokinetics and Pharmacodynamics.

Can attention bias modification augment the effect of CBT for anxiety disorders? A systematic review and meta-analysis

Ning Zhang, Chun Wang, Guojia Zhang, 2021, Psychiatry Research.

Protein Image Alignment via Piecewise Affine Transformations

Anindya Roy, Xing Liu, Florian A. Potra, 2006, J. Comput. Biol..

Orexin 2 receptor‐selective agonist danavorexton (TAK‐925) promotes wakefulness in non‐human primates and healthy individuals

Yaming Hang, H. Faessel, H. Yukitake, 2023, Journal of sleep research.

A mechanistic pharmacokinetic model for intrathecal administration of antisense oligonucleotides

A. Linninger, D. Barua, S. Iadevaia, 2023, Frontiers in Physiology.

A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson’s Disease in Participants With Leucine‐Rich Repeat Kinase 2 Mutation

F. Gheyas, G. Stebbins, K. Marek, 2021, Clinical pharmacology and therapeutics.

Altered brain function in patients with acrophobia: A voxel-wise degree centrality analysis.

Y. Zhong, Guojia Zhang, Yaming Hang, 2023, Journal of psychiatric research.

Attention bias modification for anxiety disorders in children and adolescents: A systematic review and meta-analysis

Ning Zhang, Chun Wang, Guojia Zhang, 2021, Psychiatry Research.

Opportunities and Challenges of Disease Progression Modeling in Drug Development – An IQ Perspective

T. Rieger, Yaming Hang, A. Solms, 2023, Clinical pharmacology and therapeutics.

Altered spontaneous neural activity in frontal and visual regions in patients with acrophobia.

Y. Zhong, Ning Zhang, Guojia Zhang, 2022, Journal of affective disorders.